The U.S. Food and Drug Administration has granted a South Korean company an orphan drug designation for a treatment for pancreatic cancer.
The "orphan" designation gives companies benefits for making drugs that are needed but business-wise aren't economical.
The treatment, called "Immuncell-LC," takes a patient's blood, modifies it genetically to kill certain cancer cells, and infuses it back into the patient.
Clinical trials by the manufacturer, GC Cell, showed that 10 injections were effective at a rate of 25 percent.
GC Cell will likely get tax breaks and a seven-year monopoly once the treatment is authorized, through which the company plans to move into the American market for cancer treatment.